Carl Zeiss Meditec first-half earnings halve on currency, IOL headwinds

Carl Zeiss Meditec’s first-half revenue fell 5.7% to 991.0 million euros, while adjusted EBITA more than halved to 60.5 million euros and the margin dropped to 6.1% from 10.7%. Management cited significant negative currency effects, weakness in the intraocular lens business, and a softer investment climate in the Americas. Full-year revenue is guided at 2.15 billion to 2.20 billion euros, implying a 1% to 3.5% decline, with adjusted EBITA margin expected at 8% to 10%.

Analysis

The key read-through is not just a temporary earnings miss, but a margin reset driven by factors that are only partially cyclical. FX is a blunt headwind, but the more important second-order issue is that a weak Americas investment backdrop tends to hit procedure-capex names first and recover last, so even if reported growth stabilizes, mix and pricing power may remain under pressure for several quarters. In other words, the market should not assume a near-term snapback in operating leverage simply because the top-line comparison eases.

The strategic guidance is more interesting than the current print: management is effectively signaling that the business can grow back to mid-single digits over years, but the path to a 15% margin by 2028/29 implies meaningful self-help, not just demand normalization. That creates a valuation tension versus med-tech peers with cleaner, more defensive growth profiles; investors may rotate toward names with less FX sensitivity, stronger recurring revenue, or more diversified end markets. Suppliers tied to ophthalmic capital equipment and premium IOL workflows are likely to see delayed orders before unit volumes recover, which can cascade into longer working-capital cycles across the ecosystem.

Near term, the catalysts are mostly negative: further FX volatility, weak Americas purchasing, and any additional commentary that implies reimbursement or hospital budget pressure. A reversal would require either a sharper currency tailwind or evidence that IOL demand is re-accelerating faster than capex budgets, but that is more likely a late-2025/2026 story than a next-quarter one. The contrarian angle is that the stock could already be discounting a lot of the bad news if investors believe the 2028/29 margin bridge is credible; in that case, the risk is not another earnings miss, but prolonged multiple compression as the market waits for proof.

Key Decisions for Investors

• Short the stock on any relief rally; use a 1-3 month horizon and size for a modest carry trade, as the next few prints are more likely to validate margin pressure than repair it.
• Pair trade: long a diversified med-tech leader (e.g., JNJ or ABT) vs short Carl Zeiss Meditec-equivalent exposure to isolate FX and capex-cycle risk; this favors names with recurring revenue and lower geographic earnings volatility.
• If listed options are available, buy 3-6 month puts or put spreads to express downside with defined risk; the best payoff is if guidance resets lower on continued Americas weakness.
• For long-only investors, wait for evidence of sequential stabilization in currency-neutral growth before adding; the stock is a better 2026 story than a 2025 story unless FX reverses sharply.
• Watch European healthcare capex sentiment and FX moves as the main catalysts; if the euro weakens further, consider taking partial profits on shorts because the market may temporarily look through operating weakness.